시장보고서
상품코드
1677918

인수 공통 감염증 치료 시장 규모, 점유율, 성장 분석 : 질환 유형별, 치료 유형별, 투여 경로별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Zoonotic Disease Treatment Market Size, Share, and Growth Analysis, By Disease Type (Rabies, Lyme Disease), By Treatment Type (Vaccines, Antiviral Drugs), By Administration Route, By End User, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 219 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인수 공통 감염증 치료 시장 규모는 2023년에 416억 5,000만 달러로, 2024년 442억 3,000만 달러에서 2032년에는 715억 7,000만 달러로 성장하며, 예측 기간 중(2025-2032년) CAGR은 6.2%로 성장할 전망입니다.

질병관리본부에 따르면 동물에서 사람으로 전염되는 인수공통전염병은 매년 수만 명의 미국인을 괴롭힐 것으로 예상됩니다. 급속한 도시화와 인구 증가는 특히 위생 상태가 좋지 않은 지역에서 이러한 문제를 악화시킬 가능성이 높습니다. 또한 동물성 단백질과 지방에 대한 수요 증가는 인수공통전염병 치료제 시장을 촉진할 것으로 예상됩니다. 반려동물 사육의 확산은 교감을 가져다 주지만, 동시에 질병 전파의 위험도 가져옵니다. 그러나 신흥 국가에서의 낮은 인지도와 높은 연구 비용 등의 장벽이 시장 성장에 걸림돌이 될 수 있습니다. 그럼에도 불구하고 향후 수년간 동물의 건강 요구에 맞는 혁신적인 치료법 개발로 인해 세계 시장은 확대될 것으로 예상됩니다.

목차

서론

  • 조사의 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차와 1차 데이터 방법
  • 시장 규모 예측
  • 시장의 전제조건과 제한

개요

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 사례 연구

인수 공통 감염증 치료 시장 규모 : 질환 유형별 & CAGR(2025-2032)

  • 시장 개요
  • 광견병
  • 라임병
  • 지카 바이러스
  • 웨스트 나일 바이러스
  • 한타바이러스
  • 말라리아
  • 결핵
  • 회귀열
  • 바이러스성 간염
  • 기타

인수 공통 감염증 치료 시장 규모 : 치료 유형별 & CAGR(2025-2032)

  • 시장 개요
  • 백신
  • 항바이러스제
  • 항생제
  • 면역글로불린
  • 항균제
  • 항진균제
  • 기타

인수 공통 감염증 치료 시장 규모 : 투여 경로별 & CAGR(2025-2032)

  • 시장 개요
  • 정맥내
  • 근육내
  • 경구

인수 공통 감염증 치료 시장 규모 : 최종사용자별 & CAGR(2025-2032)

  • 시장 개요
  • 병원
  • 외래 수술 센터
  • 홈케어 설정
  • 조사기관
  • 클리닉

인수 공통 감염증 치료 시장 규모 : 지역별 & CAGR(2025-2032)

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 최근 시장 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업의 기업 개요
    • 기업의 상세
    • 제품 포트폴리오 분석
    • 기업의 부문별 점유율 분석
    • 매출의 전년대비 비교(2022-2024)

주요 기업 개요

  • GlaxoSmithKline plc(UK)
  • Pfizer Inc.(USA)
  • Merck & Co., Inc.(USA)
  • Novartis AG(Switzerland)
  • Johnson & Johnson(USA)
  • F. Hoffmann-La Roche AG(Switzerland)
  • AstraZeneca plc(UK)
  • Bayer AG(Germany)
  • Eli Lilly and Company(USA)
  • AbbVie Inc.(USA)
  • Gilead Sciences, Inc.(USA)
  • Bristol-Myers Squibb Company(USA)
  • Takeda Pharmaceutical Company Limited(Japan)
  • Boehringer Ingelheim GmbH(Germany)
  • BioNTech SE(Germany)
  • Moderna, Inc.(USA)
  • Inovio Pharmaceuticals, Inc.(USA)
  • Emergent BioSolutions Inc.(USA)

결론과 제안

KSA 25.04.18

Zoonotic Disease Treatment Market size was valued at USD 41.65 billion in 2023 and is poised to grow from USD 44.23 billion in 2024 to USD 71.57 billion by 2032, growing at a CAGR of 6.2% during the forecast period (2025-2032).

According to the Centers for Disease Control and Prevention, zoonotic diseases, transmitted from animals to humans, are projected to afflict tens of thousands of Americans annually. Rapid urbanization and population growth are likely to exacerbate these issues, especially in areas with poor sanitation. Additionally, the increasing demand for animal proteins and fats is expected to drive the market for zoonotic disease treatments. The prevalence of pet ownership provides companionship but also introduces the risk of disease transmission. However, barriers such as limited awareness in developing countries and high research costs could hinder market growth. Nonetheless, the global market is poised for expansion with the development of innovative therapies tailored to animal health needs in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is being propelled by a multitude of factors, including the surging occurrence of zoonotic diseases and a growing awareness of their transmission. Additionally, the continuous development of innovative and effective treatments, alongside supportive government initiatives, plays a significant role in market growth. Furthermore, technological advancements and a rise in investments directed toward research and development further contribute to the expansion of this market. Collectively, these elements underscore the urgent need for effective treatment options and underscore the importance of addressing zoonotic diseases in public health strategies.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential of the zoonotic disease treatment market, several factors may impede its progress. The limited availability of effective treatments and the high costs associated with these therapies are significant barriers. Additionally, insufficient investment in research and development presents a further challenge. The market's growth may also be affected by the rise of generic medications and the impending patent expirations of established brands. Furthermore, a shortage of skilled professionals and inadequate healthcare infrastructure in developing countries complicate the situation. High capital requirements for research and development, coupled with a general lack of public awareness, further restrain market expansion.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing a significant upward trend, propelled by the rising incidence of zoonotic infections linked to urbanization, deforestation, and climate change. As ecosystems are disrupted, the interaction between humans and wildlife intensifies, facilitating the transmission of pathogens. This surge in disease awareness is prompting an urgent demand for innovative treatments and vaccines. Furthermore, increased government funding for research and development, alongside advancements in biotechnology, are catalyzing market expansion. With a growing focus on preventative measures and rapid response strategies, the Zoonotic Disease Treatment market is poised for robust growth in the coming years.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2025-2032)

  • Market Overview
  • Rabies
  • Lyme Disease
  • Zika Virus
  • West Nile Virus
  • Hantavirus
  • Malaria
  • Tuberculosis
  • Relapsing Fever
  • Viral Hepatitis
  • Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2025-2032)

  • Market Overview
  • Vaccines
  • Antiviral Drugs
  • Antibiotics
  • Immunoglobulins
  • Antibacterial Medication
  • Antifungal Medication
  • Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2025-2032)

  • Market Overview
  • Intravenous
  • Intramuscular
  • Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Research Institutions
  • Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2025-2032)

  • North America (Disease Type, Treatment Type, Administration Route, End User)
    • US
    • Canada
  • Europe (Disease Type, Treatment Type, Administration Route, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Disease Type, Treatment Type, Administration Route, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Moderna, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Inovio Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Emergent BioSolutions Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제